世界の先天性インスリン過剰症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Congenital Hyperinsulinism Treatment Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5672
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、105ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、先天性インスリン過剰症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ジアゾキシド、オクトレオチド、グルカゴン）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・先天性インスリン過剰症治療薬の市場動向
・企業の競争状況、市場シェア
・先天性インスリン過剰症治療薬の種類別市場規模と予測2016-2027（ジアゾキシド、オクトレオチド、グルカゴン）
・先天性インスリン過剰症治療薬の用途別市場規模と予測2016-2027（病院、診療所、その他）
・先天性インスリン過剰症治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・先天性インスリン過剰症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・先天性インスリン過剰症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・先天性インスリン過剰症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・先天性インスリン過剰症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Novo Nordisk、Eli Lilly、Fresenius Kabi、Taj Pharmaceuticals、Xeris Pharmaceuticals、Novartis、IVAX Pharmaceuticals、Sun Pharmaceutical、Chengdu Tiantaishan Pharmaceutical、Sihuan Pharmaceutical Holdings Group）
・結論

Market Analysis and Insights: Global Congenital Hyperinsulinism Treatment Drugs Market
The global Congenital Hyperinsulinism Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Congenital Hyperinsulinism Treatment Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Congenital Hyperinsulinism Treatment Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Congenital Hyperinsulinism Treatment Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Congenital Hyperinsulinism Treatment Drugs market.

Global Congenital Hyperinsulinism Treatment Drugs Scope and Market Size
Congenital Hyperinsulinism Treatment Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Congenital Hyperinsulinism Treatment Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Diazoxide
Octreotide
Glucagon

Segment by Application
Hospital
Clinic
Other

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novo Nordisk
Eli Lilly
Fresenius Kabi
Taj Pharmaceuticals
Xeris Pharmaceuticals
Novartis
IVAX Pharmaceuticals
Sun Pharmaceutical
Chengdu Tiantaishan Pharmaceutical
Sihuan Pharmaceutical Holdings Group

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Congenital Hyperinsulinism Treatment Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Diazoxide
1.2.3 Octreotide
1.2.4 Glucagon
1.3 Market by Application
1.3.1 Global Congenital Hyperinsulinism Treatment Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Congenital Hyperinsulinism Treatment Drugs Market Perspective (2016-2027)
2.2 Congenital Hyperinsulinism Treatment Drugs Growth Trends by Regions
2.2.1 Congenital Hyperinsulinism Treatment Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Congenital Hyperinsulinism Treatment Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Congenital Hyperinsulinism Treatment Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Congenital Hyperinsulinism Treatment Drugs Industry Dynamic
2.3.1 Congenital Hyperinsulinism Treatment Drugs Market Trends
2.3.2 Congenital Hyperinsulinism Treatment Drugs Market Drivers
2.3.3 Congenital Hyperinsulinism Treatment Drugs Market Challenges
2.3.4 Congenital Hyperinsulinism Treatment Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Congenital Hyperinsulinism Treatment Drugs Players by Revenue
3.1.1 Global Top Congenital Hyperinsulinism Treatment Drugs Players by Revenue (2016-2021)
3.1.2 Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Congenital Hyperinsulinism Treatment Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Congenital Hyperinsulinism Treatment Drugs Revenue
3.4 Global Congenital Hyperinsulinism Treatment Drugs Market Concentration Ratio
3.4.1 Global Congenital Hyperinsulinism Treatment Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Congenital Hyperinsulinism Treatment Drugs Revenue in 2020
3.5 Congenital Hyperinsulinism Treatment Drugs Key Players Head office and Area Served
3.6 Key Players Congenital Hyperinsulinism Treatment Drugs Product Solution and Service
3.7 Date of Enter into Congenital Hyperinsulinism Treatment Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Congenital Hyperinsulinism Treatment Drugs Breakdown Data by Type
4.1 Global Congenital Hyperinsulinism Treatment Drugs Historic Market Size by Type (2016-2021)
4.2 Global Congenital Hyperinsulinism Treatment Drugs Forecasted Market Size by Type (2022-2027)

5 Congenital Hyperinsulinism Treatment Drugs Breakdown Data by Application
5.1 Global Congenital Hyperinsulinism Treatment Drugs Historic Market Size by Application (2016-2021)
5.2 Global Congenital Hyperinsulinism Treatment Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Congenital Hyperinsulinism Treatment Drugs Market Size (2016-2027)
6.2 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Type
6.2.1 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021)
6.2.2 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027)
6.2.3 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2027)
6.3 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Application
6.3.1 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021)
6.3.2 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027)
6.3.3 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2027)
6.4 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Country
6.4.1 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2016-2021)
6.4.2 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Congenital Hyperinsulinism Treatment Drugs Market Size (2016-2027)
7.2 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Type
7.2.1 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021)
7.2.2 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027)
7.2.3 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2027)
7.3 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Application
7.3.1 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021)
7.3.2 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027)
7.3.3 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2027)
7.4 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Country
7.4.1 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2016-2021)
7.4.2 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size (2016-2027)
8.2 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Type
8.2.1 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Application
8.3.1 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Region
8.4.1 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size (2016-2027)
9.2 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Type
9.2.1 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2027)
9.3 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Application
9.3.1 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2027)
9.4 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Country
9.4.1 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size (2016-2027)
10.2 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Type
10.2.1 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Application
10.3.1 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Country
10.4.1 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Details
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Introduction
11.1.4 Novo Nordisk Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.1.5 Novo Nordisk Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Congenital Hyperinsulinism Treatment Drugs Introduction
11.2.4 Eli Lilly Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 Fresenius Kabi
11.3.1 Fresenius Kabi Company Details
11.3.2 Fresenius Kabi Business Overview
11.3.3 Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Introduction
11.3.4 Fresenius Kabi Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.3.5 Fresenius Kabi Recent Development
11.4 Taj Pharmaceuticals
11.4.1 Taj Pharmaceuticals Company Details
11.4.2 Taj Pharmaceuticals Business Overview
11.4.3 Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Introduction
11.4.4 Taj Pharmaceuticals Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.4.5 Taj Pharmaceuticals Recent Development
11.5 Xeris Pharmaceuticals
11.5.1 Xeris Pharmaceuticals Company Details
11.5.2 Xeris Pharmaceuticals Business Overview
11.5.3 Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Introduction
11.5.4 Xeris Pharmaceuticals Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.5.5 Xeris Pharmaceuticals Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Congenital Hyperinsulinism Treatment Drugs Introduction
11.6.4 Novartis Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 IVAX Pharmaceuticals
11.7.1 IVAX Pharmaceuticals Company Details
11.7.2 IVAX Pharmaceuticals Business Overview
11.7.3 IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Introduction
11.7.4 IVAX Pharmaceuticals Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.7.5 IVAX Pharmaceuticals Recent Development
11.8 Sun Pharmaceutical
11.8.1 Sun Pharmaceutical Company Details
11.8.2 Sun Pharmaceutical Business Overview
11.8.3 Sun Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Introduction
11.8.4 Sun Pharmaceutical Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.8.5 Sun Pharmaceutical Recent Development
11.9 Chengdu Tiantaishan Pharmaceutical
11.9.1 Chengdu Tiantaishan Pharmaceutical Company Details
11.9.2 Chengdu Tiantaishan Pharmaceutical Business Overview
11.9.3 Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Introduction
11.9.4 Chengdu Tiantaishan Pharmaceutical Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.9.5 Chengdu Tiantaishan Pharmaceutical Recent Development
11.10 Sihuan Pharmaceutical Holdings Group
11.10.1 Sihuan Pharmaceutical Holdings Group Company Details
11.10.2 Sihuan Pharmaceutical Holdings Group Business Overview
11.10.3 Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Introduction
11.10.4 Sihuan Pharmaceutical Holdings Group Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
11.10.5 Sihuan Pharmaceutical Holdings Group Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Congenital Hyperinsulinism Treatment Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Diazoxide
Table 3. Key Players of Octreotide
Table 4. Key Players of Glucagon
Table 5. Global Congenital Hyperinsulinism Treatment Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Congenital Hyperinsulinism Treatment Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Congenital Hyperinsulinism Treatment Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Congenital Hyperinsulinism Treatment Drugs Market Share by Regions (2016-2021)
Table 9. Global Congenital Hyperinsulinism Treatment Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Congenital Hyperinsulinism Treatment Drugs Market Share by Regions (2022-2027)
Table 11. Congenital Hyperinsulinism Treatment Drugs Market Trends
Table 12. Congenital Hyperinsulinism Treatment Drugs Market Drivers
Table 13. Congenital Hyperinsulinism Treatment Drugs Market Challenges
Table 14. Congenital Hyperinsulinism Treatment Drugs Market Restraints
Table 15. Global Congenital Hyperinsulinism Treatment Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Congenital Hyperinsulinism Treatment Drugs Market Share by Players (2016-2021)
Table 17. Global Top Congenital Hyperinsulinism Treatment Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Congenital Hyperinsulinism Treatment Drugs as of 2020)
Table 18. Ranking of Global Top Congenital Hyperinsulinism Treatment Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Congenital Hyperinsulinism Treatment Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Congenital Hyperinsulinism Treatment Drugs Product Solution and Service
Table 22. Date of Enter into Congenital Hyperinsulinism Treatment Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global Congenital Hyperinsulinism Treatment Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Congenital Hyperinsulinism Treatment Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global Congenital Hyperinsulinism Treatment Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Novo Nordisk Company Details
Table 63. Novo Nordisk Business Overview
Table 64. Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Product
Table 65. Novo Nordisk Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 66. Novo Nordisk Recent Development
Table 67. Eli Lilly Company Details
Table 68. Eli Lilly Business Overview
Table 69. Eli Lilly Congenital Hyperinsulinism Treatment Drugs Product
Table 70. Eli Lilly Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 71. Eli Lilly Recent Development
Table 72. Fresenius Kabi Company Details
Table 73. Fresenius Kabi Business Overview
Table 74. Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Product
Table 75. Fresenius Kabi Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 76. Fresenius Kabi Recent Development
Table 77. Taj Pharmaceuticals Company Details
Table 78. Taj Pharmaceuticals Business Overview
Table 79. Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product
Table 80. Taj Pharmaceuticals Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 81. Taj Pharmaceuticals Recent Development
Table 82. Xeris Pharmaceuticals Company Details
Table 83. Xeris Pharmaceuticals Business Overview
Table 84. Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product
Table 85. Xeris Pharmaceuticals Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 86. Xeris Pharmaceuticals Recent Development
Table 87. Novartis Company Details
Table 88. Novartis Business Overview
Table 89. Novartis Congenital Hyperinsulinism Treatment Drugs Product
Table 90. Novartis Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 91. Novartis Recent Development
Table 92. IVAX Pharmaceuticals Company Details
Table 93. IVAX Pharmaceuticals Business Overview
Table 94. IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product
Table 95. IVAX Pharmaceuticals Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 96. IVAX Pharmaceuticals Recent Development
Table 97. Sun Pharmaceutical Company Details
Table 98. Sun Pharmaceutical Business Overview
Table 99. Sun Pharmaceutical Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 100. Sun Pharmaceutical Recent Development
Table 101. Chengdu Tiantaishan Pharmaceutical Company Details
Table 102. Chengdu Tiantaishan Pharmaceutical Business Overview
Table 103. Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Product
Table 104. Chengdu Tiantaishan Pharmaceutical Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 105. Chengdu Tiantaishan Pharmaceutical Recent Development
Table 106. Sihuan Pharmaceutical Holdings Group Company Details
Table 107. Sihuan Pharmaceutical Holdings Group Business Overview
Table 108. Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Product
Table 109. Sihuan Pharmaceutical Holdings Group Revenue in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021) & (US$ Million)
Table 110. Sihuan Pharmaceutical Holdings Group Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Congenital Hyperinsulinism Treatment Drugs Market Share by Type: 2020 VS 2027
Figure 2. Diazoxide Features
Figure 3. Octreotide Features
Figure 4. Glucagon Features
Figure 5. Global Congenital Hyperinsulinism Treatment Drugs Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Other Case Studies
Figure 9. Congenital Hyperinsulinism Treatment Drugs Report Years Considered
Figure 10. Global Congenital Hyperinsulinism Treatment Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Congenital Hyperinsulinism Treatment Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Congenital Hyperinsulinism Treatment Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global Congenital Hyperinsulinism Treatment Drugs Market Share by Regions (2022-2027)
Figure 14. Global Congenital Hyperinsulinism Treatment Drugs Market Share by Players in 2020
Figure 15. Global Top Congenital Hyperinsulinism Treatment Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Congenital Hyperinsulinism Treatment Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Congenital Hyperinsulinism Treatment Drugs Revenue in 2020
Figure 17. Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Congenital Hyperinsulinism Treatment Drugs Market Share by Type (2016-2027)
Figure 21. North America Congenital Hyperinsulinism Treatment Drugs Market Share by Application (2016-2027)
Figure 22. North America Congenital Hyperinsulinism Treatment Drugs Market Share by Country (2016-2027)
Figure 23. United States Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Congenital Hyperinsulinism Treatment Drugs Market Share by Type (2016-2027)
Figure 27. Europe Congenital Hyperinsulinism Treatment Drugs Market Share by Application (2016-2027)
Figure 28. Europe Congenital Hyperinsulinism Treatment Drugs Market Share by Country (2016-2027)
Figure 29. Germany Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Share by Region (2016-2027)
Figure 39. China Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Congenital Hyperinsulinism Treatment Drugs Market Share by Type (2016-2027)
Figure 47. Latin America Congenital Hyperinsulinism Treatment Drugs Market Share by Application (2016-2027)
Figure 48. Latin America Congenital Hyperinsulinism Treatment Drugs Market Share by Country (2016-2027)
Figure 49. Mexico Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Share by Country (2016-2027)
Figure 55. Turkey Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Congenital Hyperinsulinism Treatment Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Novo Nordisk Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 59. Eli Lilly Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 60. Fresenius Kabi Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 61. Taj Pharmaceuticals Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 62. Xeris Pharmaceuticals Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 63. Novartis Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 64. IVAX Pharmaceuticals Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 65. Sun Pharmaceutical Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 66. Chengdu Tiantaishan Pharmaceutical Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 67. Sihuan Pharmaceutical Holdings Group Revenue Growth Rate in Congenital Hyperinsulinism Treatment Drugs Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

以下、関連資料のご紹介

世界の先天性インスリン過剰症市場規模・現状・予測（2021年-2027年）

Global Congenital Hyperinsulinism Market Size, Status and Forecast 2021-2027
QFJ1-4047 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、先天性インスリン過剰症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（手術、医薬品、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国...

世界の先天性好中球減少症治療市場規模・現状・予測（2021年-2027年）

Global Congenital Neutropenia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5131 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、先天性好中球減少症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗生物質、顆粒球コロニー刺激因子（G-CSF）、抗真菌薬）、用途別市場規模（小売薬局、病院薬局、オンライン薬局、その他）、主要地域...

世界の副鼻腔炎治療薬市場規模・現状・予測（2021年-2027年）

Global Sinusitis Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-6007 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、副鼻腔炎治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗生物質、NSAIDS、充血除去剤・粘液溶解剤、鼻洗浄キット）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメ...

世界の勃起不全治療薬市場規模・現状・予測（2021年-2027年）

Global Erectile Dysfunction Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5727 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、勃起不全治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ホスホジエステラーゼ5型阻害剤、プロスタグランジンE1）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州...

世界の不眠症治療薬市場規模・現状・予測（2021年-2027年）

Global Insomnia Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5803 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、不眠症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（処方箋睡眠補助薬、店頭販売（OTC）睡眠補助薬）、用途別市場規模（病院、薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日...

世界の生殖器ヘルペス治療薬市場規模・現状・予測（2021年-2027年）

Global Genital Herpes Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5752 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、生殖器ヘルペス治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アシクロビル、ファムシクロビル、バラシクロビル）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、...

世界の多発性硬化症薬物治療市場規模・現状・予測（2021年-2027年）

Global Multiple Sclerosis Drugs Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4534 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、多発性硬化症薬物治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（インターフェロン、免疫調節剤、免疫抑制剤）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、主要地域別市場規模（北米、...

世界の貧血治療薬市場規模・現状・予測（2021年-2027年）

Global Anemia Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-3805 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、貧血治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（サプリメント、抗生物質、免疫抑制剤、骨髄刺激剤、コルチコステロイド、遺伝子治療、鉄キレート剤）、用途別市場規模（鉄欠乏性貧血、サラセミア、再生...

世界の腹腔内感染症治療薬市場規模・現状・予測（2021年-2027年）

Global Intra-abdominal Infection Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-4387 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、腹腔内感染症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（クロラムフェニコール、ベータラクタム、キノロン、アミノグリコシド、その他）、用途別市場規模（腹腔内膿瘍、虫垂炎、憩室炎、下痢、食中毒、...

世界の多発性嚢胞腎治療薬市場規模・現状・予測（2021年-2027年）

Global Polycystic Kidney Disease Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-4730 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、多発性嚢胞腎治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ANG-3070、CIM-2、CR-8、その他）、用途別市場規模（常染色体優性多発性嚢胞腎（ADPKD）、常染色体劣性多発性嚢胞腎（A...

世界の先天性インスリン過剰症市場規模・現状・予測（2021年-2027年） Congenital hyperinsulinism (CHI) is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these oc…
世界の先天性好中球減少症治療市場規模・現状・予測（2021年-2027年） Congenital neutropenia occurs when an individual has low levels of neutrophils, a type of white blood cells. Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones such as the vertebrae, ribs, and pelvis. The congenital neutropenia treatment include antibiotics, an…
世界のレーバー先天性黒内障（LCA）市場規模・現状・予測（2021年-2027年） Leber congenital amaurosis is a kind of autosomal recessive genetic disease, it is the main genetic disease that brings about children blindness, accompany mental nerve symptom, wait like intellectual inferior, hearing obstacle, epilepsy, conus cornea can happen when some age is older or spherical c…
先天性心疾患オクルーダーのグローバル市場調査 2019年 The global Congenital Heart Disease Occluder market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Congenital Heart Disease Occluder volume and value at global level, regional level and company level. Fro…
世界のウイルス性肺炎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Viral Pneumonia Treatment Drugs Market The global Viral Pneumonia Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data i…